Markus Joerger

7.6k citations
214 papers · 5.9k · 2 hit papers · h-index 44

Impact in

  • Pharmacology top 0.2%
    • Pharmacogenetics and Drug Metabolism
  • Oncology top 2%
    • Cancer Immunotherapy and Biomarkers
    • Cancer Treatment and Pharmacology

Papers in

    • Cancer Immunotherapy and Biomarkers 37
    • Cancer Treatment and Pharmacology 20
    • Lung Cancer Research Studies 8
    • Pharmacogenetics and Drug Metabolism 38

Markus Joerger

202 papers receiving 5.8k citations

Markus Joerger's Hit Papers

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial 2021 · 254 citations
2540+3+7Years since publication100200300

Peers

Markus Joerger
Comparison fields: 5 of 123
  • Pharmacology 974
  • Oncology 1.6k
  • Cancer Research 486
  • Pulmonary and Respiratory Medicine 976
  • Pediatrics, Perinatology and Child Health 319
Replace Jean‐Pierre Armand with:
Jean‐Pierre Armand France
Hironobu Minami Japan
Danièle Ouellet United States
Sharyn D. Baker United States
Bert L. Lum United States
Marie-Christine Étienne-Grimaldi France
Wim W. ten Bokkel Huinink Netherlands
Étienne Chatelut France
Charles Erlichman United States
Federico Innocenti United States
Markus Joerger relative to Jean‐Pierre Armand France Jean‐Pierre Armand's profile →
Citations per field
00.5×1.5×2×2.4×
Jean‐Pierre Armand · 1×
Citations per year

Countries citing papers authored by Markus Joerger

Since Specialization
Citations

This map shows the geographic impact of Markus Joerger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Joerger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Joerger more than expected).

Fields of papers citing papers by Markus Joerger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Joerger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Joerger. The network helps show where Markus Joerger may publish in the future.

Co-authors

The 25 scholars most cited alongside Markus Joerger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Markus Joerger Line = papers co-authored together Markus Joerger links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 214 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps
Hit paper breakdown →
2015319
2
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial
Hit paper breakdown →
2021254
3 2004235
4 2019148
5 2010127
6 2014124
7 2009121
8 2006101
9 2007101
10 2023100
11 201899
12 200595
13 201795
14 201282
15 201982
16 200280
17 201080
18 201678
19 201076
20 201676

About Markus Joerger

Markus Joerger is a scholar working on Oncology, Pharmacology, Pulmonary and Respiratory Medicine, Pediatrics, Perinatology and Child Health and Cancer Research, having authored 214 papers that have together received 5.9k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (38 papers), Cancer Immunotherapy and Biomarkers (37 papers), Cancer Treatment and Pharmacology (20 papers), Lung Cancer Treatments and Mutations (19 papers), Pharmaceutical studies and practices (17 papers), Lung Cancer Diagnosis and Treatment (13 papers), Breast Cancer Treatment Studies (12 papers) and Lung Cancer Research Studies (8 papers). The work is most often cited by research in Pharmacology (974 citations), Oncology (1.6k citations), Cancer Research (486 citations), Pulmonary and Respiratory Medicine (976 citations) and Pediatrics, Perinatology and Child Health (319 citations). Markus Joerger has collaborated with scholars based in Switzerland, Germany and Netherlands. Frequent co-authors include Jan H.M. Schellens, Alwin D. R. Huitema, Jos H. Beijnen, Silke Gillessen, Carlo Rodolfo Largiadèr, Nicole Hagner, Thomas Cerny, Martin Früh, Ursula Amstutz and Tanja K. Froehlich. Their work appears in journals such as Annals of Oncology, Cancer Chemotherapy and Pharmacology, Lung Cancer, European Journal of Cancer and British Journal of Clinical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact